Max Healthcare Institute Ltd (MAXHEALTH) is currently trading at 1,090.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Max Healthcare Institute Limited operates a network of multi‑speciality and super‑speciality hospitals, plus two strategic business units (Max Lab and Max@Home); the Group runs ~20 facilities with ~5,200 beds, combining owned, managed and partner hospitals across major Indian metros and select PPP arrangements in Punjab. Q3 FY26 network gross revenue reached ₹2,608 crore (+10% YoY) with Network Operating EBITDA of ₹648 crore (+4% YoY) and Network PAT of ₹344 crore (+9% YoY) after two exceptional items totaling ₹55 crore, reflecting steady profitability despite payor and regulatory headwinds. Max is aggressively expanding capacity: multiple brownfield towers were partially commissioned with strong early EBITDA margins (~31%–39%), a staggered acquisition in Pune for ~450 beds, and a roadmap to nearly double bed capacity over the next 4–5 years, implying significant future revenue visibility and capital deployment. Regulatory and payor dynamics materially affected margins this quarter: CGHS tariff revisions, discontinuation of high‑value patented chemotherapy for institutional patients, a GST rate change, and temporary disruption in cashless insurer services altered payor mix and lowered sequential EBITDA margins. Digital and adjacency businesses are meaningful: digital channels contributed ~₹803 crore (~31% of gross revenue) in Q3 and Max@Home and Max Lab posted robust growth (+23% and +13% YoY respectively), signalling diversified revenue streams and stronger patient acquisition funnels outside core inpatient services.

Over the past 52 weeks, Max Healthcare Institute Ltd has traded between a low of ₹903.50 and a high of ₹1,301.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Max Healthcare Institute Ltd has a market capitalization of approximately 1,06,083.57. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Max Healthcare Institute Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 73.55 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,06,083.57 Cr, Max Healthcare Institute Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Max Healthcare Institute Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Max Healthcare Institute Ltd is 73.55. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The stock rose after Citi reiterated a buy rating with a ₹1,240 target and highlighted improved risk-reward following a correction, alongside expectations of strong medium-term growth.

Consolidated net profit rose 26% year-on-year to ₹3.01 billion, compared with ₹2.39 billion in the year-ago period.

The stock fell after Q4FY26 earnings were reported as below Street expectations, with expense growth and unchanged average bed occupancy cited as key factors.

Max Healthcare reported Q4 FY26 network PAT of Rs 387 crore, up 3% year-on-year from Rs 376 crore.